Table 3.
Association of baseline HBsAg and HBV DNA levels with HBsAg reduction
| HBsAg (IU/mL) | Groups | Number of patients (%) | Annual HBsAg log reduction (log IU/mL per year) | p value | |
|---|---|---|---|---|---|
| ≥1,000 | A | 7 (6.2 %) | 0.192 (−1.429 to 1.493) | 0.533 | |
| B | 42 (36.8 %) | 0.153 (−0.214 to 1.010) | |||
| C | 65 (57.0 %) | 0.112 (−0.180 to 0.659) | |||
| 100–1,000 | A | 12 (17.1 %) | 0.082 (−0.686 to 1.897) | 0.527 | |
| B | 28 (40.0 %) | 0.130 (−1.039 to 0.484) | |||
| C | 30 (42.9 %) | 0.105 (−1.418 to 0.405) | |||
| <100 | A | 81 (69.8 %) | 0.341 (−1.114 to 2.049) | 0.002 0.321 |
0.002 |
| B | 30 (25.8 %) | 0.122 (−0.478 to 1.468) | |||
| C | 5 (4.3 %) | 0.057 (−0.622 to 0.213) | |||
Continuous variables expressed in median (range)
The increased HBsAg reduction in patients with HBsAg <100 IU/mL and undetectable HBV DNA is highlighted in italics
HBsAg hepatitis B surface antigen, Group A HBV DNA persistently ≤20 IU/mL, Group B baseline HBV DNA 20–2,000 IU/mL, Group C baseline HBV DNA >2,000 IU/mL